CN103983787A - 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 - Google Patents
作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 Download PDFInfo
- Publication number
- CN103983787A CN103983787A CN201410221835.XA CN201410221835A CN103983787A CN 103983787 A CN103983787 A CN 103983787A CN 201410221835 A CN201410221835 A CN 201410221835A CN 103983787 A CN103983787 A CN 103983787A
- Authority
- CN
- China
- Prior art keywords
- amount
- biological sample
- vitro method
- normal control
- isotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 title claims abstract description 27
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 title claims abstract description 27
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 20
- 230000004770 neurodegeneration Effects 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000012472 biological sample Substances 0.000 claims description 58
- 239000000523 sample Substances 0.000 claims description 42
- 239000005482 chemotactic factor Substances 0.000 claims description 32
- 238000001514 detection method Methods 0.000 claims description 29
- 238000000338 in vitro Methods 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 210000005036 nerve Anatomy 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 15
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 10
- 238000003127 radioimmunoassay Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 8
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 8
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 238000001819 mass spectrum Methods 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 5
- 238000004817 gas chromatography Methods 0.000 claims description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- NIDNOXCRFUCAKQ-UMRXKNAASA-N (1s,2r,3s,4r)-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1[C@H]2C=C[C@@H]1[C@H](C(=O)O)[C@@H]2C(O)=O NIDNOXCRFUCAKQ-UMRXKNAASA-N 0.000 claims description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims description 2
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims description 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 claims description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 2
- 101150011672 CCL9 gene Proteins 0.000 claims description 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims description 2
- 102000013818 Fractalkine Human genes 0.000 claims description 2
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims description 2
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims description 2
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 claims description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 2
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 74
- 208000010877 cognitive disease Diseases 0.000 abstract description 46
- 208000027061 mild cognitive impairment Diseases 0.000 abstract description 42
- 201000010374 Down Syndrome Diseases 0.000 abstract description 8
- 206010044688 Trisomy 21 Diseases 0.000 abstract description 8
- 230000027455 binding Effects 0.000 abstract description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 238000003745 diagnosis Methods 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100029865 Glutaminyl-peptide cyclotransferase-like protein Human genes 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000007000 age related cognitive decline Effects 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000585397 Homo sapiens Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006999 cognitive decline Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000478 neocortex Anatomy 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000219173 Carica Species 0.000 description 3
- 235000009467 Carica papaya Nutrition 0.000 description 3
- 101710090339 Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 101150052909 CCL2 gene Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 description 2
- 101001129465 Homo sapiens Pyroglutamyl-peptidase 1 Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102100031108 Pyroglutamyl-peptidase 1 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VEPDWBJBPXVCEN-NSHDSACASA-N (2s)-2-amino-n-(4-methyl-2-oxochromen-7-yl)pentanediamide Chemical compound C1=C(NC(=O)[C@@H](N)CCC(N)=O)C=CC2=C1OC(=O)C=C2C VEPDWBJBPXVCEN-NSHDSACASA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- -1 prepare blood plasma Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
- G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8515408P | 2008-07-31 | 2008-07-31 | |
| US61/085,154 | 2008-07-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980130500.4A Division CN102112880B (zh) | 2008-07-31 | 2009-07-31 | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103983787A true CN103983787A (zh) | 2014-08-13 |
Family
ID=41256108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410221835.XA Pending CN103983787A (zh) | 2008-07-31 | 2009-07-31 | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 |
| CN200980130500.4A Active CN102112880B (zh) | 2008-07-31 | 2009-07-31 | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980130500.4A Active CN102112880B (zh) | 2008-07-31 | 2009-07-31 | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100028918A1 (https=) |
| EP (1) | EP2329274B1 (https=) |
| JP (1) | JP5677297B2 (https=) |
| KR (1) | KR101682728B1 (https=) |
| CN (2) | CN103983787A (https=) |
| AU (1) | AU2009275869B2 (https=) |
| BR (1) | BRPI0916601B1 (https=) |
| CA (1) | CA2731933A1 (https=) |
| EA (1) | EA025107B1 (https=) |
| IL (1) | IL210266A (https=) |
| MX (1) | MX2011001093A (https=) |
| NZ (1) | NZ590658A (https=) |
| SG (1) | SG193148A1 (https=) |
| WO (1) | WO2010012828A2 (https=) |
| ZA (1) | ZA201100177B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104946680A (zh) * | 2015-06-11 | 2015-09-30 | 深圳大学 | 用于表达qc的重组载体及其制备方法、引物、基因工程菌 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011101433A1 (en) * | 2010-02-18 | 2011-08-25 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
| SG194770A1 (en) | 2011-05-27 | 2013-12-30 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
| JP2018501482A (ja) | 2014-12-19 | 2018-01-18 | プロビオドルグ エージー | ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法 |
| KR102362919B1 (ko) * | 2016-07-08 | 2022-02-16 | 아지노모토 가부시키가이샤 | 경도 인지 장해 또는 알츠하이머형 인지증의 평가 방법 |
| KR102858457B1 (ko) * | 2023-06-07 | 2025-09-11 | 계명대학교 산학협력단 | Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008034891A2 (en) * | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| JP3590468B2 (ja) * | 1996-01-22 | 2004-11-17 | 財団法人 東京都医学研究機構 | アルツハイマー病診断薬 |
| WO2004013172A2 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| CN1784220B (zh) * | 2003-05-05 | 2011-08-03 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
| BRPI0415409A (pt) * | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| CA2554809C (en) * | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| US7592467B2 (en) * | 2005-04-11 | 2009-09-22 | Probiodrug Ag | Inhibitors of prolyl endopeptidase |
| EP1865326B1 (en) * | 2006-06-08 | 2011-09-07 | FU Berlin | Assay for the diagnosis of Alzheimer's Disease based on the determination of the ratio of secretase Aß cleavage products |
| WO2008087197A1 (en) * | 2007-01-19 | 2008-07-24 | Probiodrug Ag | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
-
2009
- 2009-07-31 US US12/533,099 patent/US20100028918A1/en not_active Abandoned
- 2009-07-31 KR KR1020117002132A patent/KR101682728B1/ko active Active
- 2009-07-31 WO PCT/EP2009/059951 patent/WO2010012828A2/en not_active Ceased
- 2009-07-31 SG SG2013056478A patent/SG193148A1/en unknown
- 2009-07-31 EP EP09781358.8A patent/EP2329274B1/en active Active
- 2009-07-31 CA CA2731933A patent/CA2731933A1/en not_active Abandoned
- 2009-07-31 NZ NZ590658A patent/NZ590658A/en unknown
- 2009-07-31 EA EA201100253A patent/EA025107B1/ru not_active IP Right Cessation
- 2009-07-31 BR BRPI0916601-7A patent/BRPI0916601B1/pt active IP Right Grant
- 2009-07-31 CN CN201410221835.XA patent/CN103983787A/zh active Pending
- 2009-07-31 CN CN200980130500.4A patent/CN102112880B/zh active Active
- 2009-07-31 AU AU2009275869A patent/AU2009275869B2/en active Active
- 2009-07-31 JP JP2011520526A patent/JP5677297B2/ja active Active
- 2009-07-31 MX MX2011001093A patent/MX2011001093A/es active IP Right Grant
-
2010
- 2010-12-26 IL IL210266A patent/IL210266A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00177A patent/ZA201100177B/en unknown
-
2015
- 2015-03-12 US US14/645,821 patent/US20150247180A1/en not_active Abandoned
-
2016
- 2016-12-14 US US15/378,328 patent/US20170097365A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008034891A2 (en) * | 2006-09-21 | 2008-03-27 | Probiodrug Ag | Novel genes related to glutaminyl cyclase |
Non-Patent Citations (3)
| Title |
|---|
| DAGMAR SCHLENZIG等: "Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides", 《BIOCHEMISTRY》 * |
| DANIELA GALIMBERTI等: "Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease", 《NEUROBIOLOGY OF AGING》 * |
| STEPHAN SCHILLING等: ""Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathology", 《NATURE MEDICINE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104946680A (zh) * | 2015-06-11 | 2015-09-30 | 深圳大学 | 用于表达qc的重组载体及其制备方法、引物、基因工程菌 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102112880A (zh) | 2011-06-29 |
| EP2329274B1 (en) | 2015-12-02 |
| IL210266A (en) | 2016-04-21 |
| ZA201100177B (en) | 2012-02-29 |
| CN102112880B (zh) | 2014-06-25 |
| US20150247180A1 (en) | 2015-09-03 |
| BRPI0916601B1 (pt) | 2021-05-25 |
| HK1155813A1 (en) | 2012-05-25 |
| WO2010012828A2 (en) | 2010-02-04 |
| JP5677297B2 (ja) | 2015-02-25 |
| SG193148A1 (en) | 2013-09-30 |
| BRPI0916601A2 (pt) | 2015-11-10 |
| US20170097365A1 (en) | 2017-04-06 |
| MX2011001093A (es) | 2011-03-15 |
| AU2009275869A1 (en) | 2010-02-04 |
| EP2329274A2 (en) | 2011-06-08 |
| EA201100253A1 (ru) | 2011-10-31 |
| WO2010012828A3 (en) | 2010-05-06 |
| KR20110049781A (ko) | 2011-05-12 |
| IL210266A0 (en) | 2011-03-31 |
| JP2011529571A (ja) | 2011-12-08 |
| KR101682728B1 (ko) | 2016-12-05 |
| AU2009275869B2 (en) | 2015-05-21 |
| EA025107B1 (ru) | 2016-11-30 |
| CA2731933A1 (en) | 2010-02-04 |
| NZ590658A (en) | 2012-07-27 |
| US20100028918A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| El‐Agnaf et al. | Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease | |
| Jahn et al. | Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers | |
| US9733260B2 (en) | Biochemical markers for neurodegenerative conditions | |
| US20110166035A1 (en) | Novel diagnostic method | |
| JP5755149B2 (ja) | 方法 | |
| US20170097365A1 (en) | Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases | |
| JP5904418B2 (ja) | 前頭側頭葉変性の鑑別診断のための生体外の方法 | |
| Nutu et al. | Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases | |
| TW201830016A (zh) | 使用G72蛋白質與SLC7A11mRNA作為生物標記來診斷與治療阿茲海默氏症的方法 | |
| US20090263822A1 (en) | In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases | |
| JP2005539228A (ja) | 軽度の認知障害を示すアルツハイマー患者特有の診断方法 | |
| EP2653872B1 (en) | Biomarker for amyloid-beta -related neurological disorders | |
| JP2005513480A (ja) | トロンボスポンジンを使用する痴呆の診断および治療 | |
| HK1197762A (en) | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases | |
| HK1155813B (en) | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases | |
| JP2009513960A (ja) | 神経変性疾患を診断するためのｉｎｖｉｔｒｏ方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1197762 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140813 |
|
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1197762 Country of ref document: HK |